Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers

NCT00779688 · View on ClinicalTrials.gov ↗

Study Summary

This registry will collect data from patients routinely undergoing an ERCP and Cellvizio endomicroscopy procedure (and optionally an additional cholangiopancreatoscopy procedure) due to suspected pancreatic or bile duct cancer. The objective is to determine if endomicroscopy images collected using the marketed Cellvizio device may help endoscopists more accurately diagnose, in conjunction with traditional tissue sampling techniques, whether a suspected lesion is malignant or benign.

Interventions

  • DEVICE Probe-based confocal laser endomicroscopy

Study Locations (6)

Colorado

  • University of Colorado Hospital — Aurora

Massachusetts

  • Beth Israel Deaconess Medical Center — Boston

New York

  • New York Presbyterian Hospital/Columbia University Medical Center — New York

Pennsylvania

  • University of Pittsburgh Medical Center — Pittsburgh

Other

  • Institut Paoli-Calmettes — Marseille

Bavaria

  • Klinikum rechts der Isar — Munich

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2008-11
Est. Completion 2010-10

Sponsor

Mauna Kea Technologies

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00779688

The ClinicalTrials.gov registry entry for NCT00779688 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mauna Kea Technologies, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention — of which Probe-based confocal laser endomicroscopy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00779688 reports 6 study locations spanning 6 distinct geographic areas — top geographies include Colorado, Massachusetts, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00779688 about?

NCT00779688 is a clinical study titled "A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers". This registry will collect data from patients routinely undergoing an ERCP and Cellvizio endomicroscopy procedure (and optionally an additional cholangiopancreatoscopy procedure) due to suspected pancreatic or bile duct cancer. The objective is to determine if endomicroscopy images collected using t...

What is the current status of trial NCT00779688?

This trial is currently completed. The enrollment target is 130 participants. The study started on 2008-11. Estimated completion is 2010-10.

What conditions does trial NCT00779688 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Bile Duct Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00779688?

The interventions under investigation include: Probe-based confocal laser endomicroscopy (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00779688?

This trial is sponsored by Mauna Kea Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00779688 being conducted?

This trial has 6 study locations across Colorado, Massachusetts, New York, Pennsylvania, Bavaria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial